Prediabetic State Clinical Trial
Official title:
Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
Verified date | March 2017 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to examine whether the use of genetic test information and/or
health coaching in patient risk counseling for heart disease and diabetes affect health
behaviors and health outcomes in active-duty Air Force (ADAF), beneficiaries or dependents
and Air Force retiree patients.
Total of 400 subjects will be enrolled. They will be randomly(like flipping a coin)assigned
to 4 groups: 1)Standard risk assessment (SRA)only; 2)SRA plus genetic risk information
(SRA+G); 3)SRA plus health coaching (SRA+HC); or 4)SRA, genetic risk information, and health
coaching (SRA+G+HC). Subjects randomized to the two genetic arms will have blood collected
for testing of investigational coronary heart disease (CHD) and type 2 diabetes (T2D) risk
markers. Participants in the two groups that include health coaching will be assigned to a
trained certified health coach for a period of 6 months. The duration of the study is 12
months with 3 in person visits (baseline, 6 months and 12 months) and completion of surveys
at 6 weeks and 3 month time points.
Status | Completed |
Enrollment | 220 |
Est. completion date | February 1, 2017 |
Est. primary completion date | February 1, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Age 18 to 65 years - Willingness and ability to provide informed consent - Have an active email address and internet access - Physical exam in the last 12 months with the following documented evaluations in EMR (Electronic Medical record): 1. Blood pressure 2. Height and weight 3. Fasting blood glucose or Hemoglobin A1C (HbA1c) 4. Lipid panel (TC, LDL, HDL, TRIG) with at least one of them outside of the normal ranges defined as: i.BMI = 25 kg/m2 (BMI = weight [kg] / ht [m]2) ii.FPG > 100 AND = 125 mg/dL iii.HbA1c > 5.7% = 6.4% iv.SBP = 130 mmHg v.TC = 200 mg/dL vi.TRIG = 150 mg/dL vii.LDL = 129 mg/dL Exclusion Criteria: - Projected deployment in the upcoming 6 months - Diagnosed type 2 diabetes - Diagnosed coronary heart disease (CHD) -(Myocardial Infarction, or documented CHD) - Inability to ambulate or participate in physical activity - Serious chronic disease related complications or conditions that could significantly affect study outcomes [currently treated cancer, renal failure, cardiovascular accident (CVA) with residual effects on functioning - Current participation in another research study - Spouse, partner or other household member already participating in this study protocol |
Country | Name | City | State |
---|---|---|---|
United States | David Grant Medical Center | Fairfield | California |
Lead Sponsor | Collaborator |
---|---|
Duke University | David Grant U.S. Air Force Medical Center |
United States,
Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, Willerson JT, Boerwinkle E. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun;2(3):279-85. doi: 10.1161/CIRCGENETICS.108.817338. Epub 2009 Apr 21. — View Citation
Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20;355(3):241-50. — View Citation
McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010 Dec 9;363(24):2339-50. doi: 10.1056/NEJMra0906948. Review. — View Citation
Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA. 2010 Feb 17;303(7):648-56. doi: 10.1001/jama.2010.118. — View Citation
Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, Kopin LA, Lungelow D; Cardiovascular Health Intervention Research and Translation Network Work Group on Global Coronary Heart Disease Risk. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010 Feb 8;170(3):230-9. doi: 10.1001/archinternmed.2009.516. Review. — View Citation
Vorderstrasse AA, Ginsburg GS, Kraus WE, Maldonado MC, Wolever RQ. Health coaching and genomics-potential avenues to elicit behavior change in those at risk for chronic disease: protocol for personalized medicine effectiveness study in air force primary c — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dietary Intake as Measured by Percent Energy From Fat | Dietary intake as measured by percent energy from fat, adjusted for baseline | 12 months | |
Primary | Dietary Intake as Measured by Daily Grams of Fiber | Dietary intake as measured by daily grams of fiber, adjusted for baseline | 12 months | |
Primary | Physical Activity, as Measured by the Stanford Brief Activity Survey (SBAS) | The Stanford Brief Activity Survey is a 2-item survey that assesses two categories of physical activity - work and leisure. There are five options for degree of activity to choose from in each of the two areas of activity. Activity categories (inactive, light-intensity activity, moderate-intensity activity, hard-intensity activity, and very hard-intensity) are represented in a table of different patterns. Degree of work activity is represented on the vertical axis and degree of leisure activity is represented on the horizontal axis. The overall activity level category is determined by where the two responses intersect. | 12 months | |
Primary | Smoking Status | 12 months | ||
Primary | Medication Adherence as Measured by Morisky Adherence Survey MMAS8 | Scores of the MMAS-8 range from 0 to 8. A score below 6 indicates low adherence, a score between 6 < 8 medium adherence and a score of 8 high adherence. | 12 months | |
Primary | Weight | Weight in kg | 12 months | |
Primary | Waist Circumference | Waist circumference in cm | 12 months | |
Primary | Systolic Blood Pressure | Systolic blood pressure in mmHg | 12 months | |
Primary | Diastolic Blood Pressure | Diastolic blood pressure in mmHg | 12 months | |
Primary | High-density Lipoprotein (HDL) | High-density lipoprotein (HDL) in mg/dL | 12 months | |
Primary | Low-density Lipoprotein (LDL) | Low-density lipoprotein (LDL) in mg/dL | 12 months | |
Primary | Triglycerides | Triglycerides in mg/dL | 12 months | |
Secondary | Fasting Blood Glucose | Adjusted for baseline | 12 months | |
Secondary | Body Mass Index (BMI) | 12 months | ||
Secondary | Total Cholesterol | Adjusted for baseline | 12 months | |
Secondary | AF Composite Fitness Scores | Last annual fitness exam result, collected as pass or fail | 12 months | |
Secondary | Framingham Risk Score (FRS) | 12 months | ||
Secondary | Diabetes Risk Score | 12 months | ||
Secondary | Perceived Risk for Coronary Heart Disease (CHD) | Investigator developed questions assessing level of personal perceived risk, fear, anger, worry regarding CHD risk. The consequences subscale ranges from 6-30. Higher scores on the consequences represent strongly held beliefs about negative consequences of the illness. The personal control subscale ranges from 6-30 and the treatment control subscale ranges from 2-10. Higher scores on the personal control and treatment control represent positive beliefs about the controllability of the illness. The emotional representations scores range from 6-30. Higher score indicates higher levels of worry or anxiety about risk of illness. | 6 months | |
Secondary | Perceived Risk for Type 2 Diabetes (T2D) | Investigator developed questions assessing level of personal perceived risk, fear, anger, worry regarding T2D risk. The consequences subscale ranges from 6-30. Higher scores on the consequences represent strongly held beliefs about negative consequences of the illness. The personal control subscale ranges from 6-30 and the treatment control subscale ranges from 2-10. Higher scores on the personal control and treatment control represent positive beliefs about the controllability of the illness. The emotional representations scores range from 6-30. Higher score indicates higher levels of worry or anxiety about risk of illness. | 6 months | |
Secondary | Patient Activation Score | Patient activation is the degree to which patients accept an active role in their healthcare, and have the knowledge, skills and confidence to take care of their health. When scored as a continuous variable, the range is from 0 to 100, with higher numbers indicating greater levels of patient activation. | 12 months | |
Secondary | Stages of Change | These evidence-based questions are validated and based upon the Transtheoretical Model and assess an individual's readiness to make behavioral change in 5 health behavior domains (dietary intake, exercise, weight loss, smoking cessation, and medication adherence). | 6 months | |
Secondary | Depression, as Measured by the Beck Depression Inventory (BDI) | The Beck Depression Inventory is a 21-item measure that assesses self-reported symptoms of depression. It has been heavily used in research linking depression to heart disease. Scores range from 0-63, with 0 = minimal depression and 63 = severe depression. | 6 months | |
Secondary | Unmanaged Stress as Measured by the Perceived Stress Scale (PSS) | The PSS is a 10 item survey assessing feelings and thoughts of stress. Scores range from 0-40 with higher scores indicating higher perceived stress. | 6 months | |
Secondary | Social Isolation | Single item to assess for availability of support person, where No=no support person. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05424107 -
A Mediterranean Intervention on Prediabetic Children
|
N/A | |
Recruiting |
NCT02681887 -
Effect of Melatonin on Cardiometabolic Risk- FULL
|
Phase 3 | |
Completed |
NCT04088461 -
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
|
Phase 4 | |
Recruiting |
NCT02561377 -
Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)
|
N/A | |
Completed |
NCT02551640 -
Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients
|
N/A | |
Completed |
NCT02678390 -
Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes
|
N/A | |
Completed |
NCT02459691 -
Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)
|
N/A | |
Completed |
NCT01479933 -
Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes
|
N/A | |
Completed |
NCT01671293 -
Multicomponent Telecare Model for Supporting Prediabetes Patients
|
N/A | |
Completed |
NCT00960973 -
The Effect of Vitamin K Supplementation on Glucose Metabolism
|
Phase 4 | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Recruiting |
NCT05123963 -
Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors
|
N/A | |
Recruiting |
NCT05340868 -
Genetics of the Acute Response to Oral Semaglutide
|
N/A | |
Recruiting |
NCT04984421 -
IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE)
|
N/A | |
Recruiting |
NCT04134650 -
Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes
|
Phase 3 | |
Recruiting |
NCT04131582 -
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
|
Phase 3 | |
Recruiting |
NCT05347030 -
Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population
|
N/A | |
Completed |
NCT04074148 -
Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal
|
N/A | |
Recruiting |
NCT05050266 -
Enhancing Mental and Physical Health of Women Veterans
|
N/A | |
Completed |
NCT02684565 -
Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects
|
N/A |